Tirzepatide · Regulatory label update

FDA supplemental approval: Zepbound (Efficacy)

U.S. Food and Drug Administration · August 26, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA supplemental approval action for tirzepatide (Zepbound) based on efficacy, issued 26 August 2026. The regulatory record does not contain clinical trial data, efficacy results, or comparative evidence; it documents only the approval decision and product formulations approved.

What was studied

Regulatory label update.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval action for tirzepatide (Zepbound) efficacy; regulatory decisions do not themselves constitute clinical evidence and do not report trial outcomes.

Caveats

This is a regulatory approval record, not a clinical trial report; no efficacy data, sample size, endpoints, or comparators are presented.
The source does not report trial outcomes, effect sizes, or statistical comparisons.
No information on indication, patient population studied, or basis for the efficacy determination is provided in this document.
Clinical trial results supporting this approval are not included in the source text provided.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory record; no trial design described in source text.

Directness

insufficient

Regulatory action; clinical trial outcomes not reported in this document.

Consistency

insufficient

No comparative or replication data presented in regulatory record.

Risk of bias

insufficient

Regulatory record does not describe trial conduct or risk of bias assessment.

Sample adequacy

insufficient

No sample size or trial population data reported in regulatory document.

What is missing. This record has no key findings, reported figures. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application NDA217806. This is a regulatory action record, not a clinical study. Brand name: ZEPBOUND. Active ingredient: TIRZEPATIDE. Sponsor: ELI LILLY AND CO. Submission type: SUPPL (supplement). Submission class: Efficacy. Approval status date: 2026-08-26. Products: ZEPBOUND, SOLUTION, SUBCUTANEOUS, TIRZEPATIDE 60MG/2.4ML (25MG/ML); ZEPBOUND KWIKPEN, SOLUTION, SUBCUTANEOUS, TIRZEPATIDE 60MG/2.4ML (25MG/ML); ZEPBOUND, SOLUTION, SUBCUTANEOUS, TIRZEPATIDE 40MG/2.4ML (16.7MG/ML); ZEPBOUND, SOLUTION, SUBCUTANEOUS, TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML).

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

ELI Lilly ANDTirzepatide